Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
| Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
|---|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 | 0 |
| % | 0 | 0 | 0 | 0 | 0 |
[Dilip Davda] The company operates in a highly competitive and fragmented segment with many players around. It has posted growth in its financial performance for the reported periods. It is on an expansion spree with a cancer hospital, educational and healthcare management institute establishment. Based on its FY23 performance, the issue appears reasonably priced. This segment is witnessing market fancy. Investors may consider investment for the medium to long-term rewards. Read detail review...
Asarfi Hospital Limited peer comparison with similar listed entities. () (As on March 31, 2023)
| Company Name | EPS (Rs) | P/E (x) | RoNW (%) | |
|---|---|---|---|---|
| EPS Basic | EPS Diluted | |||
| Asarfi Hospital Limited | 7.58 | 7.58 | 19.16 | |
| Shalby Limited | 7.48 | 7.48 | 24.23 | 7.30 |
| Global Health Limited | 12.57 | 12.57 | 54.98 | 13.43 |
| KMC Speciality Hospitals (India) Ltd. | 1.64 | 1.64 | 41.10 | 23.51 |
Asarfi Hospital IPO Reviews, analysis and views by popular members. Read Asarfi Hospital Ltd. IPO reviews by retail investors to find recommended ipo to buy.
| Review By | Apply | May Apply | Neutral | Avoid |
|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 |
| % | 0.00 | 0.00 | 0.00 | 0.00 |
| Member | Review |
|---|---|
| No recommendation found. Be the first to post the recommendation. | |
Note:
RHP